| 1 |
How might using gold nanoparticles in electrochemical sensors enhance early-stage disease detection?
|
2. By increasing surface interactions for more accurate biomarker capture |
|
Gold nanoparticles have a big surface area. This helps them catch tiny disease markers better, so doctors can detect disease early. |
3.1. Properties of nanomaterials
The high surface area to volume ratio of nanomaterials enhances their reactivity and interaction with other substances. At the nanoscale, quantum effects can alter optical, electrical, and magnetic properties, enabling novel functionalities. Nanomaterials often exhibit superior strength, flexibility, and durability compared to their bulk counterparts. Nanotechnology is a transformative field with the potential to revolutionize numerous industries through the development of materials and devices with unique properties and functionalities. In medical diagnostics, the integration of nanotechnology with electrochemical sensors has opened up new possibilities for highly sensitive, specific, and rapid detection of various biomarkers and pathogens [45,46]. As research and development in this field continue to advance, the scope of nanotechnology's impact is expected to expand, driving innovation and improving quality of life.
4. Integration of nanotechnology with electrochemical sensors
4.1. Methods of integrating nanomaterials into electrochemical sensors
Electrodeposition can be used to coat electrodes with metal nanoparticles (e.g., gold, platinum, Fig. 9), enhancing the sensor's catalytic activity and electron transfer rates. Electrodeposition of conductive polymers, such as polyaniline or polypyrrole, incorporating nanomaterials can improve the sensor's conductivity and stability.
https://www.sciencedirect.com/science/article/pii/S2214180424001156?ref=pdf_download&fr=RR-2&rr=95c5ad5bd9c144c0#s0120 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following best explains how label-free electrochemical sensors support point-of-care medical diagnostics?
|
3. They provide direct measurement of target molecules with minimal preparation |
|
Label-free sensors eliminate the need for chemical labels, enabling rapid, simple diagnostics that are ideal for point-of-care (POC) use. These sensors don’t need special labels or dyes. They can find disease markers quickly and are easy to use in |
Source: Digital Sensing Technologies – Section 2: Digital sensors for cancer care |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Why is electrochemical transduction considered advantageous over optical transduction in medical diagnostic sensors?
|
2. It is more compatible with smartphone integration for remote analysis |
|
These sensors make electric signals, which can be sent to a smartphone. This makes it easy for doctors to check results from far away. |
https://www.sciencedirect.com/science/article/pii/S2590137025000780?ref=cra_js_challenge&fr=RR-1#sec4
4.1. Digital sensors applications in cancer detection |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which action would most effectively increase specificity in a sensor designed to detect a single disease biomarker?
|
3. Functionalizing the electrode with disease-specific aptamers |
|
Aptamers are like tiny keys made for certain diseases. Adding them helps the sensor find only the disease it’s looking for. |
https://www.sciencedirect.com/science/article/pii/S2214180424001156?ref=pdf_download&fr=RR-2&rr=95c5ad5bd9c144c0#s0120
1. Introduction
1.1. Importance of medical diagnostics
The integration of nanotechnology into electrochemical sensors marks a significant advancement in the field of medical diagnostics [2]. Nanotechnology involves the manipulation of materials at the nanoscale (one billionth of a meter) which endows these materials with unique properties that can enhance the performance of diagnostic sensors. Nanomaterials such as nanoparticles, nanowires, nanotubes, quantum dots, and graphene, exhibit high surface area-to-volume ratios, unique electrical properties, and enhanced chemical reactivity making them ideal for use in electrochemical sensors [3]. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
In a scenario where a sensor must detect ultra-low concentrations of a cancer biomarker, which modification is most critical?
|
3. Incorporating nanostructures to increase surface-to-volume ratio |
|
Tiny structures like nanotubes give more surface area. This helps the sensor catch even very small amounts of disease markers. |
https://www.sciencedirect.com/science/article/pii/S2214180424001156?ref=pdf_download&fr=RR-2&rr=95c5ad5bd9c144c0#s0100
3.3. Properties of nanomaterials relevant to sensing |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Why might two electrochemical sensors using the same nanomaterial produce inconsistent results?
|
3. Variations in nanomaterial synthesis affect structural uniformity |
|
If the nanomaterials are made a little differently, they might not work the same. That’s why two similar sensors can give different results. |
https://www.sciencedirect.com/science/article/pii/S2214180424001156?ref=pdf_download&fr=RR-2&rr=95c5ad5bd9c144c0#s0300
7.1.1. Technical challenges
Ensuring reproducibility and consistency in sensor performance is a major technical challenge [135]. Variability in the synthesis and fabrication of nanomaterials can lead to inconsistent sensor responses. Minor variations in size, shape, and surface properties of nanomaterials can significantly impact their electrochemical behavior, making it difficult to achieve reliable and reproducible results.
The stability and durability of nanomaterial-based sensors are critical for their long-term use [136]. Many nanomaterials, such as metal nanoparticles, are prone to oxidation and agglomeration, which can degrade their performance over time. Additionally, sensors exposed to biological samples and harsh environments may experience fouling and degradation, affecting their longevity and reliability.
Integrating nanotechnology-based sensors with existing diagnostic platforms and electronic systems presents another technical challenge [137]. Compatibility with current medical devices, data acquisition systems, and communication protocols is essential for seamless integration. Ensuring that nanomaterial-based sensors can be easily incorporated into existing healthcare infrastructures requires careful design and standardization.
Electrochemical sensors can be susceptible to signal interference and noise, which can compromise their accuracy and sensitivity [138]. Nanomaterials, while enhancing sensor performance, may also introduce additional sources of noise. Addressing these issues requires the development of advanced signal processing techniques and sensor designs that minimize interference and enhance signal-to-noise ratios. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
Which characteristic makes nanotechnology-based electrochemical sensors especially suitable for wearable medical devices?
|
3. They allow miniaturization without losing sensitivity |
|
Nanomaterials help make tiny sensors that still work well. That’s why they’re great for things like smartwatches and patches. |
6.1. Sensitivity and specificity
The effectiveness of diagnostic tools, including electrochemical sensors, is largely determined by their sensitivity and specificity. Sensitivity refers to a sensor's ability to correctly identify those with the disease (true positive rate), while specificity refers to its ability to correctly identify those without the disease (true negative rate). Nanotechnology has significantly enhanced these metrics in electrochemical sensors, making them highly effective for medical diagnostics.
https://www.sciencedirect.com/science/article/pii/S2214180424001156?ref=pdf_download&fr=RR-2&rr=95c5ad5bd9c144c0#s0145 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What would likely happen if the bioreceptor layer is poorly immobilized on the sensor surface?
|
3. Target biomolecules may not bind effectively, leading to weak or inaccurate signals |
|
If the part that catches the disease marker isn’t fixed well, it won’t work properly. That means weak or wrong results. |
6.1.1. Enhancements in sensitivity
Nanomaterials such as nanoparticles, nanowires, and nanotubes provide a significantly increased surface area compared to bulk materials. This increased surface area allows for a higher density of biomolecular interactions, thereby enhancing the sensor's sensitivity. AuNPs have been used to modify the surface of electrodes in glucose sensors, significantly increasing the surface area available for enzyme immobilization. This modification results in higher sensitivity, enabling the detection of glucose at much lower concentrations than traditional sensors [111]. Nanomaterials exhibit excellent electrical conductivity, which enhances electron transfer between the electrode and the target biomolecules. This property is crucial for achieving high sensitivity in electrochemical sensors. The CNTs have been integrated into cholesterol sensors to improve electron transfer efficiency, leading to a substantial increase in sensitivity for cholesterol detection [112]. Nanotechnology enables various signal amplification strategies that enhance sensitivity. Techniques such as the use of nanocatalysts and nanostructured electrodes amplify the electrochemical signals generated during the detection process. Quantum dots have been utilized in electrochemical sensors for the detection of cancer biomarkers. Their unique optical and electronic properties allow for significant signal amplification, improving the sensor's sensitivity [113].
6.1.2. Enhancements in specificity
Nanomaterials can be functionalized with specific recognition elements such as antibodies, aptamers, or molecularly imprinted polymers (MIPs) to selectively bind target molecules, thereby enhancing specificity.
The GO has been functionalized with specific antibodies for the detection of cardiac biomarkers. The selective binding of these antibodies to the target biomarker enhances the specificity of the sensor [114].
Nanomaterial surfaces can be engineered to minimize non-specific binding, which is crucial for improving specificity. Surface modifications such as polyethylene glycol (PEG) coating reduce non-specific interactions. PEG-coated nanoparticles have been used in electrochemical sensors to reduce non-specific binding in the detection of pathogens, thus enhancing specificity [115]. Nanotechnology enables the development of multiplexed sensors that can simultaneously detect multiple biomarkers. This capability allows for cross-verification of results, improving overall specificity.
Electrochemical sensors incorporating quantum dots for multiplexed detection have been developed to simultaneously identify several cancer biomarkers with high specificity [116].
The integration of nanotechnology into electrochemical sensors has led to remarkable improvements in sensitivity and specificity, which are crucial for accurate and reliable medical diagnostics. The increased surface area, enhanced electron transfer, and signal amplification capabilities provided by nanomaterials have significantly boosted sensitivity. Meanwhile, the selective binding properties, reduction of non-specific binding, and ability to perform multiplexed detection have enhanced specificity. These advancements are paving the way for the development of highly effective diagnostic tools that can provide early and precise detection of various diseases. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
Which modification would most directly enhance electron transfer in the sensor system?
|
2. Incorporating carbon nanotubes on the electrode surface |
|
Carbon nanotubes help electricity move better, giving stronger signals. |
6.1.1. Enhancements in sensitivity
Nanomaterials such as nanoparticles, nanowires, and nanotubes provide a significantly increased surface area compared to bulk materials. This increased surface area allows for a higher density of biomolecular interactions, thereby enhancing the sensor's sensitivity. AuNPs have been used to modify the surface of electrodes in glucose sensors, significantly increasing the surface area available for enzyme immobilization. This modification results in higher sensitivity, enabling the detection of glucose at much lower concentrations than traditional sensors [111]. Nanomaterials exhibit excellent electrical conductivity, which enhances electron transfer between the electrode and the target biomolecules. This property is crucial for achieving high sensitivity in electrochemical sensors. The CNTs have been integrated into cholesterol sensors to improve electron transfer efficiency, leading to a substantial increase in sensitivity for cholesterol detection [112]. Nanotechnology enables various signal amplification strategies that enhance sensitivity. Techniques such as the use of nanocatalysts and nanostructured electrodes amplify the electrochemical signals generated during the detection process. Quantum dots have been utilized in electrochemical sensors for the detection of cancer biomarkers. Their unique optical and electronic properties allow for significant signal amplification, improving the sensor's sensitivity [113]. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
How can digital sensing technologies best support personalized cancer care?
|
2. By collecting real-time data on patient-specific symptoms and responses |
|
Digital sensors track a patient’s health in real-time, helping doctors adjust treatment. |
6.1. Use of digital sensor platforms in specific cancer types
The application of digital sensor platforms across various cancer types demonstrates their adaptability and effectiveness in identifying disease-specific biomarkers for accurate diagnosis and staging. SERS platform is one of the emerging strategies in digital sensors for the ultra-sensitive detection of cancer-related biomarkers. One prominent example is the use of SERS platforms in detecting lung cancer-associated biomarkers at molecular level (Park et al., 2017). A SERS-based exosome sensor, for instance, has demonstrated effectiveness in differentiating lung cancer stages by analyzing blood exosomes with deep learning algorithms (Shin et al., 2020). The complexity and heterogeneity of the molecular composition of human blood exosomes were addressed by training on datasets derived from healthy individuals. In parallel, the evolution of VOC-based cancer detection has significantly transformed into sophisticated diagnostic tools with minimal invasiveness (Hakim et al., 2012; Lavra et al., 2015; Phillips, 1992; Yucel et al., 2018). A six-metal oxide-sensor e-nose optimized for lung cancer-related VOCs achieved a sensitivity, specificity, and accuracy rates of 95 %, 100 %, and 97.2 %, respectively, for the breath analysis conducted on a total of 118 individuals (Kononov et al., 2019).
Beyond respiratory cancer, digital sensor platforms have significantly advanced both the early detection and monitoring of breast cancer. Wearable technological innovations, for example, have opened new avenues for continuous, non-invasive monitoring of breast cancer (Bahrami et al., 2014; Mahmood et al., 2021). A notable development in this area is the “Smart Bra,” a wearable device incorporating a coplanar waveguide based monopole antenna capable of detecting variations in the dielectric properties between healthy and cancerous breast tissue (Elsheakh et al., 2023). The device is effective for detecting tumors larger than 10 mm, and has been reported to be a promising tool for at-home breast examination and early intervention. Complementing wearable technologies, laboratory-based digital sensors are revolutionizing breast cancer diagnostics and treatment monitoring. A 3D-printed nanocomposite graphene electrode platform has shown potential for electrochemical monitoring of breast cancer cell adhesion and chemosensitivity to various anti-cancer drugs (Muñoz et al., 2023). By assessing key breast cancer biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2, this approach aids in predicting tumor behavior and tailoring targeted therapies. To improve the accuracy of tissue classification, Liu et al. have developed a ddPCR, combined with ML algorithms, which offers high accuracy in differentiating between healthy and malignant tissues (Liu et al., 2021). Using dual fluorescence channels for precise detection of mRNA markers derived from small EVs, ddPCR reached an accuracy of 95 % in distinguishing breast cancer patients from healthy individuals, and a 74.6 % accuracy rate in classifying benign versus malignant tumors.
Prostate cancer diagnostics have similarly benefited from the digital advancements in accurate and sensitive biomarker detection. While traditional screening methods such as PSA measurement and digital rectal exams remain common, innovative digital sensor platforms offer more precise, non-invasive alternatives (Mistry and Cable, 2003). A notable development has been the digital ELISA, which utilizes fL-sized wells, termed as single molecule arrays, significantly lowering the LOD and allowing the identification of biomarkers at even sub-fM concentrations (Rissin et al., 2010). Further advancements have enabled detection at aM and even sub-zM levels, improving biomarker sensitivity and facilitating non-invasive diagnostics in complex clinical samples (Dhanapala et al., 2020; Wu et al., 2020). Another breakthrough is the FET-based biosensor for PSA detection from urine samples with an accuracy of 99 % uisng a multimarker approach (Kim et al., 2021) (Fig. 10). This approach expands POC options for prostate cancer by providing highly accurate, non-invasive early diagnosis that is sensitive to specific, pathophysiologically unique biomarkers. Microarray platforms have also amplified detection capabilities, identifying cancer biomarkers at pg and ag concentrations levels (Cohen et al., 2020). These advances in digital sensor technology are refining prostate cancer diagnostics for early intervention and improved long-term outcomes.
Fig. 10
Download: Download high-res image (525KB)
Download: Download full-size image
Fig. 10. Schematic illustration of FET-based multimarker sensing platform coupled with ML algorithm for PSA detection. Adapted from reference (Kim et al., 2021).
6.2. Clinical trials and validation studies
As digital biosensor technologies progress toward clinical adoption, robust validation through clinical trials is essential to establish their diagnostic reliability and regulatory approval. To ensure safety, efficacy, and reliability, rigorous clinical trials and validation studies are essential as these technologies transition from lab-based research to practical healthcare applications (Khozin et al., 2017; O'Connor et al., 2017). Diverse patient populations and clinical settings confirm the ability of digital biosensors to improve diagnostic accuracy and patient outcomes. This section explores recent advancements in clinical trials and validation methods for digital sensor platforms in cancer detection, including innovative approaches like ML and cross-site validation, which enhance diagnostic precision.
Studies validating digital biosensors in clinical scenarios provide strong evidence for their utility. For instance, a 2024 study by Lee et al. utilized a cross-site validation approach for a lung cancer eNose detection system, analyzing breath samples from 231 participants across two institutions using a CNN augmented by data enhancement (Lee et al., 2024). The study classified participants as lung cancer patients, healthy controls, or those with structural lung diseases or chronic obstructive pulmonary disease and achieved an area under the ROC curve of 0.95, with a sensitivity of 0.91 and specificity of 0.77, underscoring the diagnostic capability of eNose systems across sites. Other cross-site validation studies for eNose systems have shown accuracies ranging from 79 % to 86 %, emphasizing the robustness of these devices for cancer detection (Di Natale et al., 2003; V.A et al., 2021; van de Goor et al., 2018).
Beyond cancer diagnosis and treatment planning, digital biosensors also play a critical role in monitoring patients during treatment or post-surgery. One example is a study conducted by Panda et al., which utilizes smartphone accelerometers to track post-surgical recovery among cancer patients, offering a more personalized and objective measure of physical activity (Panda et al., 2020). Another study involved 71 patients outfitted with Fitbit devices following intensive care for metastatic cancer surgery, aiming to predict readmission risk within 30 and 60 days. Findings suggest that continuous physical activity monitoring via wearable devices may identify patients at greater risk for readmission, supporting timely interventions that could enhance recovery and reduce healthcare costs (Low et al., 2018). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
If a clinician needs to monitor fatigue and motion in cancer patients at home, which device should be prioritized?
|
2. Smart accelerometers in wearables |
|
Smart accelerometers in wearables can track movement and tiredness, helping doctors understand patient activity at home. |
6.2. Clinical trials and validation studies
As digital biosensor technologies progress toward clinical adoption, robust validation through clinical trials is essential to establish their diagnostic reliability and regulatory approval. To ensure safety, efficacy, and reliability, rigorous clinical trials and validation studies are essential as these technologies transition from lab-based research to practical healthcare applications (Khozin et al., 2017; O'Connor et al., 2017). Diverse patient populations and clinical settings confirm the ability of digital biosensors to improve diagnostic accuracy and patient outcomes. This section explores recent advancements in clinical trials and validation methods for digital sensor platforms in cancer detection, including innovative approaches like ML and cross-site validation, which enhance diagnostic precision.
Studies validating digital biosensors in clinical scenarios provide strong evidence for their utility. For instance, a 2024 study by Lee et al. utilized a cross-site validation approach for a lung cancer eNose detection system, analyzing breath samples from 231 participants across two institutions using a CNN augmented by data enhancement (Lee et al., 2024). The study classified participants as lung cancer patients, healthy controls, or those with structural lung diseases or chronic obstructive pulmonary disease and achieved an area under the ROC curve of 0.95, with a sensitivity of 0.91 and specificity of 0.77, underscoring the diagnostic capability of eNose systems across sites. Other cross-site validation studies for eNose systems have shown accuracies ranging from 79 % to 86 %, emphasizing the robustness of these devices for cancer detection (Di Natale et al., 2003; V.A et al., 2021; van de Goor et al., 2018).
Beyond cancer diagnosis and treatment planning, digital biosensors also play a critical role in monitoring patients during treatment or post-surgery. One example is a study conducted by Panda et al., which utilizes smartphone accelerometers to track post-surgical recovery among cancer patients, offering a more personalized and objective measure of physical activity (Panda et al., 2020). Another study involved 71 patients outfitted with Fitbit devices following intensive care for metastatic cancer surgery, aiming to predict readmission risk within 30 and 60 days. Findings suggest that continuous physical activity monitoring via wearable devices may identify patients at greater risk for readmission, supporting timely interventions that could enhance recovery and reduce healthcare costs (Low et al., 2018). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Why is combining sensor data with patient-reported outcomes (PROs) important in digital cancer care?
|
3. It allows a holistic understanding of patient experience |
|
Sensor data shows physical changes, while PROs explain feelings. Together, they give a full picture of the patient’s condition. |
4.3.3. Potential for early detection and personalized medicine
The integration of wearable sensors into healthcare systems offers significant potential for early disease detection and personalized treatment strategies, enabling timely interventions based on individual health data. Wearable sensors bridge the gap between traditional healthcare practices and digital health solutions, offering proactive and preventive care. For instance, wearable ECG monitors can detect irregular heart rhythms before they escalate, and biochemical sensors monitoring biomarkers in sweat (like glucose or lactate) could identify metabolic diseases, such as diabetes (Gawali and Wadhai, 2017; Kulkarni et al., 2024). The integration of wearable sensors with AI and ML algorithms further expands their scope of applications. These technologies can analyze large datasets from wearable sensors to identify trends that indicate specific medical conditions for timely interventions and customization of treatment methods (Greco et al., 2023). Additionally, wearable sensors can monitor patients' responses to therapies, including radiotherapy and chemotherapy. By tracking physiological parameters such as heart rate, blood pressure, and body temperature, these sensors can minimize side effects and allow real-time adjustments to treatment regimens, improving outcomes and quality of life for patients. Wearable sensors thus represent a critical advancement in the shift towards personalized medicine in oncology (Gawali and Wadhai, 2017) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
A hospital invested in wearable digital monitoring but received low engagement from patients. Which of the following is most likely a contributing factor?
|
3. Low digital health literacy among patients |
|
Patients may not understand how to use digital health tools, which reduces participation. |
7.3. Addressing ethical and privacy concerns
Digital sensor platforms have considerable ethical and privacy concerns that necessitate thorough examination to foster patient confidence and facilitate successful implementation for oncological diagnosis. These concerns are primarily centered on the application of AI, the safeguarding of data privacy, and the involvement of patients in the process (Kelkar et al., 2024; Sulaieva et al., 2024). AI raises ethical questions about equity, patient dignity, and autonomy in cancer diagnosis. It is of utmost importance to ensure that AI systems are designed to respect patient rights and promote inclusivity (Kelkar et al., 2024; Sulaieva et al., 2024). In addition to these, patient information security is another critical point for the digital sensor platforms in cancer diagnosis (Smith et al., 2016; Sweeney et al., 2023). Patients usually share health data using digital sensor platforms, but they do not have any information about the use of their information (Smith et al., 2016). Innovative technologies such as Elsy software were developed to protect the collected patient data, which uses a two-factor authentication to protect privacy while maintaining data usability (Ray et al., 2022). Also, few regulations were obtained to secure the patient's information, such as HIPAA and GDPR (Sweeney et al., 2023). They guide the ethical use of data, emphasizing the need for secure data practices, including encryption and access controls. Digital sensor platforms have significant potential to improve cancer diagnosis, but to protect patient rights and improve the quality of healthcare generally, ethical and privacy concerns must be carefully considered. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
Which future trend is most aligned with the development of emerging digital cancer platforms?
|
2. Creation of pocket-sized biosensing tools integrated with smartphones |
|
The article talks about miniaturized wearable devices and smartphone integration as future directions. |
7.4. Future trends and potential breakthroughs
The future of digital sensor platforms for cancer diagnosis has gained significance through innovative technologies that enhance detection methods' sensitivity, speed, and personalization. These future trends and potential breakthroughs could revolutionize early cancer detection and patient care. These upcoming advancements are mainly based on avenues such as multiplexed diagnostic platforms, functionalized nanomaterials, AI and digital medicine expansion, technological biomarker integration, real-time data collection, wearable technologies, and holistic approaches (Annunziata et al., 2024; Borkar et al., 2024; Ge et al., 2022; Kaya et al., 2022; Parihar et al., 2022; Putri et al., 2024; Scott and Thompson, 2024; Tian et al., 2024; Xu et al., 2023). While the potential of digital sensor platforms holds great promise in cancer diagnostics, regulatory considerations and technological advancements must evolve to facilitate their integration into standard cancer care clincal practices. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How can real-time symptom monitoring positively affect treatment decisions?
|
3. By enabling rapid intervention before major deterioration |
|
Monitoring symptoms in real-time helps doctors act early, improving survival and outcomes. |
1.2. Early detection of cancer via digital sensor platforms
Innovative digital sensor platforms have gained increasing attention for their ability to enhance early cancer detection through real-time, sensitive, and non-invasive monitoring. Early detection and precise diagnosis of cancer possess the potential to significantly reduce mortality. Identifying cancer at initial stages allows for interventions that are often less aggressive, minimizes metastatic risks, and provides a higher probability of successful treatments. Further, early diagnosis enhances clinical decision-making by supporting toxicity monitoring and the customization of therapies. Within the landscape of assay development, digital sensor platforms facilitate real-time, non-invasive, and sensitive cancer detection (Ferrari, 2005; Uttley et al., 2016; Wu and Qu, 2015). Microelectronics, biotechnology, AI, and ML platforms synergistically enable accurate, rapid, and sensitive detection of biological signals that are often undetectable by conventional methods (Ganjalizadeh et al., 2023; Kammarchedu et al., 2022; Shajari et al., 2023; Zheng et al., 2005). Traditional diagnostic tools, while effective, are not cost-effective often require complex processing, and are time and labor intensive. In contrast, digital biosensors are facile, offer portability, and the ability to deliver continuous and real-time, patient-specific diagnostic information. This capability for continuous, highly personalized disease monitoring is crticial for early cancer diagnosis and treatment customization (Kim et al., 2021; Shehada et al., 2015). Furthermore, the integration of digital sensors with mobile and cloud-based platforms enables instantaneous data transmission and analysis. This not only facilitates personalized patient management but also contributes to large-scale data pools, advancing research in diagnostic biomarkers and therapy development via big data analytics (Clay et al., 2021; Krishnamurthi et al., 2020). By offering transformative improvements in diagnostic sensitivity, real-time data accessibility, and the potential for AI-driven insights, digital sensor platforms are poised to redefine oncological diagnostics, bridging the gap between early detection, precision medicine, and improved patient outcomes (Adir et al., 2020). Denis et al. (2017) reported that employing a weekly web-based symptom self-reporting system in clinic patients resulted in higher overall survival (19 months vs. 12 months) and improved performance level at the time of relapse. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which technology is best suited to detect rare cancer biomarkers with high precision?
|
3. Basic pulse oximeter |
|
Digital ELISA can detect very low levels of biomarkers, even in complex samples. |
4.1. Digital sensors applications in cancer detection
The integration of digital sensor technologies with oncology has opened new possibilities for accurate, efficient, and non-invasive cancer detection. The advances in digital sensor platforms are critical for the development of sophisticated cancer diagnostics, as illustrated in Figure 3
Numerous studies have highlighted the growing role of digital biosensors in cancer diagnostics. For example, Klein et al. developed a biosensor array using giant magnetoresistive (GMR) technology to simultaneously detect multiple ovarian cancer biomarkers with high sensitivity. The integration of GMR sensors in a multiplexed array allowed for the detection and quantification of several biomarkers, showcasing enhanced diagnostic capabilities (Klein et al., 2019). Similarly, Hu et al. created an advanced digital immunoassay coupled with a microfluidic chip for detecting multiple cancer biomarkers with improved diagnostic accuracy (Hu et al., 2017). Another digital biosensor platform based on a label-free SERS method was developed by Kim et al. for a non-invasive diagnosis of breast cancer using human tears (Kim et al., 2017). The SERS-based sensor demonstrated high sensitivity and specificity, proving its potential for early breast cancer detection through the analysis of tear samples (Kim et al., 2020). Li et al. demonstrated a sensitive, label-free biosensor using single-crystalline graphene (SCG) for the simultaneous detection of multiple lung cancer biomarkers. The monolayer SCG flakes were produced by the chemical vapor deposition method and are subsequently suspended to prevent any interference from substrates and grain boundaries. This approach resulted in a digital biosensor with enhanced sensitivity, achieving a limit of detection of ∼0.1 pg/mL, which enables early diagnosis while also demonstrating high specificity and improved uniformity as compared to the traditional polycrystalline graphene sensors (Li et al., 2015). Peng et al. developed a digital biosensor for detecting lung cancer associated volatile organic compounds (VOCs) in exhaled breath by dispersing gold nanoparticles (AuNPs) onto an electrode surface, which enhanced the electrochemical detection of target biomolecules (Peng et al., 2009). The deployment of digital biosensors for cancer diagnosis offers early detection, real-time monitoring, and personalized care with high sensitivity and specificity. Integration of these sensors with mobile and cloud technologies provides accessibility and non-invasive diagnosis options, which proves their significance in advancing precision medicine and improving patient outcomes. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
Why is collaboration between data scientists and clinicians essential in digital oncology platforms?
|
3. Data insights require clinical validation for real-world use |
|
Data scientists process the sensor data, but only clinicians know what that means for real treatment. |
6.2. Clinical trials and validation studies
As digital biosensor technologies progress toward clinical adoption, robust validation through clinical trials is essential to establish their diagnostic reliability and regulatory approval. To ensure safety, efficacy, and reliability, rigorous clinical trials and validation studies are essential as these technologies transition from lab-based research to practical healthcare applications (Khozin et al., 2017; O'Connor et al., 2017). Diverse patient populations and clinical settings confirm the ability of digital biosensors to improve diagnostic accuracy and patient outcomes. This section explores recent advancements in clinical trials and validation methods for digital sensor platforms in cancer detection, including innovative approaches like ML and cross-site validation, which enhance diagnostic precision.
Studies validating digital biosensors in clinical scenarios provide strong evidence for their utility. For instance, a 2024 study by Lee et al. utilized a cross-site validation approach for a lung cancer eNose detection system, analyzing breath samples from 231 participants across two institutions using a CNN augmented by data enhancement (Lee et al., 2024). The study classified participants as lung cancer patients, healthy controls, or those with structural lung diseases or chronic obstructive pulmonary disease and achieved an area under the ROC curve of 0.95, with a sensitivity of 0.91 and specificity of 0.77, underscoring the diagnostic capability of eNose systems across sites. Other cross-site validation studies for eNose systems have shown accuracies ranging from 79 % to 86 %, emphasizing the robustness of these devices for cancer detection (Di Natale et al., 2003; V.A et al., 2021; van de Goor et al., 2018).
Beyond cancer diagnosis and treatment planning, digital biosensors also play a critical role in monitoring patients during treatment or post-surgery. One example is a study conducted by Panda et al., which utilizes smartphone accelerometers to track post-surgical recovery among cancer patients, offering a more personalized and objective measure of physical activity (Panda et al., 2020). Another study involved 71 patients outfitted with Fitbit devices following intensive care for metastatic cancer surgery, aiming to predict readmission risk within 30 and 60 days. Findings suggest that continuous physical activity monitoring via wearable devices may identify patients at greater risk for readmission, supporting timely interventions that could enhance recovery and reduce healthcare costs (Low et al., 2018). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
Which outcome is most likely when cancer patients actively use digital health tools to track their condition?
|
2. They engage more actively in shared treatment decisions |
|
Patients who track their health data understand their condition better and talk more with doctors. |
4.3.3. Potential for early detection and personalized medicine
The integration of wearable sensors into healthcare systems offers significant potential for early disease detection and personalized treatment strategies, enabling timely interventions based on individual health data. Wearable sensors bridge the gap between traditional healthcare practices and digital health solutions, offering proactive and preventive care. For instance, wearable ECG monitors can detect irregular heart rhythms before they escalate, and biochemical sensors monitoring biomarkers in sweat (like glucose or lactate) could identify metabolic diseases, such as diabetes (Gawali and Wadhai, 2017; Kulkarni et al., 2024). The integration of wearable sensors with AI and ML algorithms further expands their scope of applications. These technologies can analyze large datasets from wearable sensors to identify trends that indicate specific medical conditions for timely interventions and customization of treatment methods (Greco et al., 2023). Additionally, wearable sensors can monitor patients' responses to therapies, including radiotherapy and chemotherapy. By tracking physiological parameters such as heart rate, blood pressure, and body temperature, these sensors can minimize side effects and allow real-time adjustments to treatment regimens, improving outcomes and quality of life for patients. Wearable sensors thus represent a critical advancement in the shift towards personalized medicine in oncology (Gawali and Wadhai, 2017) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
A research team is developing a highly selective electrochemical sensor for detecting cancer biomarkers in blood. Based on the diagram, which combination of nanoparticle properties would most likely enhance both specificity and signal sensitivity?
|
2. Small spherical particles with antibody-conjugated targeting ligands |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
A hospital is planning to adopt a single digital sensing platform to support a wide range of diagnostic applications. Based on the image, which of the following most justifies this decision?
|
2. One platform can be customized to detect toxins, cancer biomarkers, and heavy metals using interchangeable biorecognition elements |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|